Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder with Comorbid Major Depressive Disorder: A Case Series of Eight Patients
Research Square September 26, 2025 Soria López, Cinto Segalàs, Eva Real et al.
Abstract Background: Intranasal esketamine has gained attention as a rapidly acting intervention for treatment-resistant depression, and there is growing interest in its potential anti-obsessional effects. To our knowledge, no published case series has focused on intranasal esketamine in patients with both treatment-resistant obsessive–compulsive disorder (TR‑OCD) and comorbid major depression...